PSORIASIS-TARGETS AND THERAPY : Impact Factor & More
eISSN: 2230-326XpISSN: 2230-326X
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
PSORIASIS-TARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in PSORIASIS-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in PSORIASIS-TARGETS AND THERAPY
Bidirectional Associations Between Substance Abuse and Psoriasis: A Prospective Cohort Study
- 7 Jan 2026
- Psoriasis: Targets and Therapy
Prevalence of Genital Psoriasis and Its Impact on Patients’ Sexual Life in Routine Care: Epidemiologic Survey in Germany
- 1 Jan 2026
- Psoriasis: Targets and Therapy
Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP–GPP Overlap
- 1 Jan 2026
- Psoriasis: Targets and Therapy
Real-World Experience of Guselkumab in the Elderly Population
- 26 Dec 2025
- Psoriasis: Targets and Therapy
Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study
- 24 Dec 2025
- Psoriasis: Targets and Therapy
Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis – A Pilot Study on a Mouse Model
- 18 Dec 2025
- Psoriasis: Targets and Therapy
Bidirectional Associations Between Substance Abuse and Psoriasis: A Prospective Cohort Study
- 7 Jan 2026
- Psoriasis: Targets and Therapy
Prevalence of Genital Psoriasis and Its Impact on Patients’ Sexual Life in Routine Care: Epidemiologic Survey in Germany
- 1 Jan 2026
- Psoriasis: Targets and Therapy
Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP–GPP Overlap
- 1 Jan 2026
- Psoriasis: Targets and Therapy
Real-World Experience of Guselkumab in the Elderly Population
- 26 Dec 2025
- Psoriasis: Targets and Therapy
Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study
- 24 Dec 2025
- Psoriasis: Targets and Therapy
Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis – A Pilot Study on a Mouse Model
- 18 Dec 2025
- Psoriasis: Targets and Therapy
FAQs on PSORIASIS-TARGETS AND THERAPY
How long has PSORIASIS-TARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of PSORIASIS-TARGETS AND THERAPY?
How many articles did PSORIASIS-TARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for PSORIASIS-TARGETS AND THERAPY?
Who is the publisher of PSORIASIS-TARGETS AND THERAPY?
